跳至主要内容
临床试验/NCT07034274
NCT07034274已完成不适用

National Tunisian Clinical Registry on CardioVascular Secondary Prevention Clinical

Dacima Consulting1 个研究点 分布在 1 个国家目标入组 7,284 人开始时间: 2025年6月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
7,284
试验地点
1
主要终点
Compliance

研究概览

简要总结

A non-interventional, national longitudinal multicenter study of CV secondary prevention in Tunisia

详细描述

The NATURE-STOP-CHD study is carried out in Tunisia at cardiology consultations in hospitals and in the liberal sector. The study is a longitudinal non-interventional registry of patient undergoing secondary CV prevention. The data collected are managed by the DACIMA Clinical Suite® platform, which complies with international standards: FDA 21 CFR part 11 (Food and Drug Administration 21 Code of Federal Regulations part 11), HIPPA (Health Insurance Portability and Accountability Act), ICH (International Conference on Harmonisation), MedDRA (Medical Dictionary for Regulatory Activities). The DACIMA Clinical Suite® platform allows to track the data entered, check for inconsistencies and missing data, and schedule monitoring visits. A Steering Committee is set up to monitor patient inclusions, verify data sources, perform audit trails and prepare the statistical analysis plan for the study.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age > 18 years and < 80 years
  • •Patients who have been hospitalized for at least one acute coronary event with coronary revascularization, either percutaneous or surgical by coronary artery bypass grafting, or who have confirmed coronary artery disease requiring optimal medical treatment for more than 6 months
  • •Coronary event happening in 2024
  • •Informed, read and signed consent

排除标准

  • •Familial hypercholesterolemia

研究组 & 干预措施

Coronary Event

Patient with any coronary event

结局指标

主要结局

Compliance

时间窗: From enrollment to the end of the follow-up (12 months)

Number of subjects with sufficient adherence to their cardiovascular medication

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验